TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine
Brief Summary: The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.


Options:
A: Arm Label: MenACWY + Tdap + HPV; Type: EXPERIMENTAL; Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine | Arm Label: MenACWY →Tdap → HPV; Type: EXPERIMENTAL; Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine | Arm Label: Tdap →MenACWY → HPV; Type: EXPERIMENTAL; Interventions: Biological: Tdap Vaccine | Intervention Type: BIOLOGICAL; Name: Novartis Meningococcal ACWY Conjugate Vaccine; Assigned to Arm(s): MenACWY + Tdap + HPV | Intervention Type: BIOLOGICAL; Name: Tdap Vaccine; Assigned to Arm(s): Tdap →MenACWY → HPV | Intervention Type: BIOLOGICAL; Name: Novartis Meningococcal ACWY Conjugate Vaccine; Assigned to Arm(s): MenACWY →Tdap → HPV
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (CervarixTM) | Arm Label: Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-BTM | Intervention Type: BIOLOGICAL; Name: GSK580299 (CervarixTM); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-BTM; Assigned to Arm(s): Engerix Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Intervention Type: BIOLOGICAL; Name: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): 1, 2, 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women
Brief Summary: The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In Situ (AIS), and genital warts.


Options:
A: Intervention Type: PROCEDURE; Name: CO2 laser surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ultrasonic surgical aspiration; Assigned to Arm(s): N/A
B: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cidofovir; Type: EXPERIMENTAL; Interventions: Drug: cidofovir, Genetic: DNA methylation analysis, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Procedure: biopsy, Procedure: histopathologic examination | Intervention Type: DRUG; Name: cidofovir; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: histopathologic examination; Assigned to Arm(s): Cidofovir
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women
Brief Summary: The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In Situ (AIS), and genital warts.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
C: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women
Brief Summary: The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In Situ (AIS), and genital warts.


Options:
A: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V504, Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Biological: Comparator: Placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: V504; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Brief Summary: The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.


Options:
A: Intervention Type: PROCEDURE; Name: CO2 laser surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ultrasonic surgical aspiration; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
C: Arm Label: Cidofovir; Type: EXPERIMENTAL; Interventions: Drug: cidofovir, Genetic: DNA methylation analysis, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Procedure: biopsy, Procedure: histopathologic examination | Intervention Type: DRUG; Name: cidofovir; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Cidofovir | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): Cidofovir | Intervention Type: PROCEDURE; Name: histopathologic examination; Assigned to Arm(s): Cidofovir
D: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Brief Summary: The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.


Options:
A: Arm Label: SAFE Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SAFE Behavioral Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SAFE Behavioral Intervention; Assigned to Arm(s): SAFE Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
D: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Brief Summary: The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.


Options:
A: Arm Label: Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 2 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 3 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine 580299; Assigned to Arm(s): Cervarix 1 Group, Cervarix 2 Group, Cervarix 3 Group
B: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study).
Brief Summary: This study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).


Options:
A: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
B: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3
D: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month

Answer: A